Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
$0.00
-40.0%
$0.00
$0.00
$0.06
$6K1.0510,994 shs8,972 shs
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$0.00
$0.00
$0.00
$6K1.6183,499 shsN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
$0.00
$0.00
$0.00
$7K-0.0726,442 shsN/A
ONE Bio Corp. stock logo
ONBI
ONE Bio
$0.00
-96.0%
$0.00
$0.00
$0.01
$2K-5.75N/A11,100 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
-40.00%-40.00%-40.00%-40.00%-99.37%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00%0.00%0.00%+150.00%+150.00%
MusclePharm Co. stock logo
MSLP
MusclePharm
0.00%0.00%0.00%0.00%-83.33%
ONE Bio Corp. stock logo
ONBI
ONE Bio
-93.33%-93.33%-93.33%-93.33%-93.33%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/AN/AN/AN/AN/A
ONE Bio Corp. stock logo
ONBI
ONE Bio
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00
N/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00
N/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
0.00
N/AN/AN/A
ONE Bio Corp. stock logo
ONBI
ONE Bio
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$1.91M0.00N/AN/A$0.47 per share0.00
MusclePharm Co. stock logo
MSLP
MusclePharm
$50.04M0.00N/AN/A($0.94) per share0.00
ONE Bio Corp. stock logo
ONBI
ONE Bio
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
-$114.53MN/A0.00N/AN/AN/AN/A5/5/2025 (Estimated)
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/A
MusclePharm Co. stock logo
MSLP
MusclePharm
-$12.87M-$0.58N/AN/AN/A-38.51%N/A-169.56%N/A
ONE Bio Corp. stock logo
ONBI
ONE Bio
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
N/AN/AN/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/AN/A
ONE Bio Corp. stock logo
ONBI
ONE Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.24
1.35
1.35
MusclePharm Co. stock logo
MSLP
MusclePharm
N/A
0.25
0.23
ONE Bio Corp. stock logo
ONBI
ONE Bio
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.31%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.64%
MusclePharm Co. stock logo
MSLP
MusclePharm
15.49%
ONE Bio Corp. stock logo
ONBI
ONE Bio
N/A

Insider Ownership

CompanyInsider Ownership
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
1.02%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
1.61%
MusclePharm Co. stock logo
MSLP
MusclePharm
60.70%
ONE Bio Corp. stock logo
ONBI
ONE Bio
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
12018.98 million18.79 millionNo Data
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
7058.73 million57.79 millionNot Optionable
MusclePharm Co. stock logo
MSLP
MusclePharm
2033.39 million13.12 millionNot Optionable
ONE Bio Corp. stock logo
ONBI
ONE Bio
3608.37 millionN/ANot Optionable

Recent News About These Companies

One Bio raises $27 million in Series A funding
AI captures history as virtual biographer in new venture
Zenas Bio: Recent IPO With Late-Stage Candidate
One-on-one with legendary coach Bobby Knight
One Piece's Creator Talks Nami's Biological Parents
Mini-Med School

Media Sentiment Over Time

Evelo Biosciences stock logo

Evelo Biosciences NASDAQ:EVLO

$0.0003 0.00 (-40.00%)
As of 05/2/2025 09:57 AM Eastern

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Genocea Biosciences stock logo

Genocea Biosciences NASDAQ:GNCA

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

MusclePharm stock logo

MusclePharm OTCMKTS:MSLP

MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.

ONE Bio stock logo

ONE Bio OTCMKTS:ONBI

$0.0002 0.00 (-96.00%)
As of 05/2/2025 09:34 AM Eastern

ONE Bio Corp., an agritech company, together with its subsidiaries, utilizes green process manufacturing to produce raw chemicals and herbal extracts, natural supplements, and organic products. The company operates through two business units, Chemical and Herbal Extracts (CHE) and Organic Products (OP). The CHE business unit engages in the development, manufacture, and commercialization of bio-ecological products and over-the-counter products utilizing the extractions of tobacco leaves and various other plant materials. It produces chemical and herbal extracts for use in a range of health and wellness products, including chemical extracts comprising Solanesol and Coenzyme Q10; and herabal extracts, such as Resveratrol, 5-Hydroxytryptophan, Ganoderma Tea, and powdered and particulate fertilizers. This business unit distributes its products through independent third party distributors, universities, and hospital research centers to the bio-health industry and raw chemical intermediates industry in the People's Republic of China. The OP business unit manufactures various consumer and commercial use health and energy drinks, organic food products, and fertilizers primarily based on bamboo in the People's Republic of China. Its products include boiled bamboo shoot cans, boiled bamboo shoot cans with vacuum packing, boiled mixed vegetables, and boiled seasoned vegetables, as well as Kamameshi, a Japanese rice dish. This segment distributes its products directly to supermarket chains, hotels, hospitals, and restaurants, as well as through a network of independent third party distributors. ONE Bio Corp. exports its products to Japan, southeast Asia, Europe, and North America. The company was formerly known as ONE Holdings, Corp. and changed its name to ONE Bio Corp. in November 2009. ONE Bio Corp. was incorporated in 2000 and is headquartered in Aventura, Florida.